|
ACMS
|
Advisory Committee on Medicines Scheduling
|
|
ACNEM
|
Australasian College of Nutritional and Environmental Medicine
|
|
AMA
|
Australian Medical Association
|
|
AP
|
Authorised Prescriber
|
|
ARTG
|
Australian Register of Therapeutic Goods
|
|
CAS
|
Controlled Access Scheme
|
|
CBD
|
Cannabidiol
|
|
COAG
|
Council of Australian Governments
|
|
CTN
|
Clinical Trials Notification Scheme
|
|
Department
|
Department of Health
|
|
DVA
|
Department of Veterans' Affairs
|
|
EAA
|
Epilepsy Action Australia
|
|
Ethics committee
|
Human research ethics committee
|
|
GMP
|
Good Manufacturing Practice
|
|
GP
|
General practitioner
|
|
Lambert Initiative
|
Lambert Initiative for Cannabinoid Therapeutics, University of Sydney
|
|
MBS
|
Medicare Benefits Schedule
|
|
McMillan review
|
Review into the 2016 Medicinal Cannabis amendments to the Narcotic Drugs Act 1967
|
|
MCIA
|
Medicinal Cannabis Industry Australia
|
|
MCUA
|
Medical Cannabis Users Association of Australia
|
|
ND Act
|
Narcotic Drugs Act 1967
|
|
NICM HRI
|
National Institute of Complementary Medicine Health Research Institute
|
|
ODC
|
Office of Drug Control
|
|
PBAC
|
Pharmaceutical Benefits Advisory Committee
|
|
PBS
|
Pharmaceutical Benefits Scheme
|
|
Poisons Standard
|
Uniform Scheduling of Medicines and Poisons
|
|
RACGP
|
Royal Australian College of General Practitioners
|
|
RPBS
|
Repatriation Pharmaceutical Benefits Scheme
|
|
S2, S3, etc.
|
Schedule 2, Schedule 3, etc. in the Uniform Scheduling of Medicines and Poisons
|
|
SAS
|
Special Access Scheme
|
|
SAS-A, SAS-B, SAS-C
|
Special Access Scheme Category A, Special Access Scheme Category B, Special Access Scheme Category C
|
|
TG Act
|
Therapeutic Goods Act 1989
|
|
TGA
|
Therapeutic Goods Administration
|
|
TGO 93
|
Therapeutic Goods (Standard for Medicinal Cannabis) (TGO 93) Order 2017
|
|
THC
|
Delta-9-tetrahydrocannabinol
|
|
UIC
|
United in Compassion
|
|
UN Single Convention
|
United Nations Single Convention on Narcotic Drugs
|